Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

December 21, 2020December 21, 2020

PHA Names New President and CEO, Matt Granato

News, PH News

Matt J. Granato is the newly named president and CEO of the Pulmonary Hypertension Association (PHA), the nonprofit group announced. Granato, who has more than 20 years of experience ... Read more

December 16, 2020December 16, 2020

Bosentan May Lower Risk of PH in Certain Scleroderma Patients

News

Treatment with bosentan may lower the risk of developing pulmonary hypertension (PH) and help stabilize lung function in scleroderma patients with digital ulcers, a study suggests. Patients who never ... Read more

November 23, 2020November 23, 2020

Sotatercept Improves Exercise Capacity in PAH, Early SPECTRA Data Show

News

Treatment with Acceleron Pharma’s sotatercept leads to substantial improvements in cardiac parameters, as well as exercise tolerance and capacity, in people with pulmonary arterial hypertension (PAH) on standard therapies, early ... Read more

September 23, 2020September 23, 2020

New Virtual Tool May Allow Fast, Accurate PH Diagnosis During COVID-19, Study Says

News, PH News

A new virtual tool, called VEST, is aiding clinicians in remotely diagnosing people with Group 1 pulmonary hypertension (PH) per the World Health Organization (WHO) classification, a new study ... Read more

September 14, 2020September 14, 2020

Switching to Adempas Improves Clinical Outcomes in Intermediate-risk PAH Patients, Phase 4 Trial Shows

News

People with intermediate-risk pulmonary arterial hypertension (PAH) who failed to respond adequately to phosphodiesterase-5 inhibitors (PDE5i) show significant benefits when transitioned to Adempas (riociguat) treatment, a Phase 4 trial ... Read more

August 10, 2020August 10, 2020

5-year Survival Rate Lower in Congenital Heart Disease Patients With PAH

News, PAH News

The five-year survival rate is markedly reduced among adults with pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD), compared with other types of CHD, real-world data from ... Read more

July 31, 2020July 31, 2020

Klotho Protein Supplements Improve Pulmonary, Cardiac Function in BPD Rat Model

News, PH News

Preterm babies with the lung condition bronchopulmonary dysplasia (BPD) — a risk factor for the development of pulmonary hypertension (PH) — have lower levels of the anti-aging-associated protein Klotho, ... Read more

June 26, 2020June 26, 2020

Way of Fine-tuning Vagus Nerve Stimulation, Potential PH Therapy, Seen

News

Anodal block, a technique based on electrical nerve stimulation, allows for the selective activation of fibers in the vagus nerve, a key nerve that runs through the neck and ... Read more

June 22, 2020June 22, 2020

Tiny RNA Molecule, MicroRNA-483, May Help Ease PAH, Early Study Finds

News, PAH News

Increasing the levels of a tiny RNA molecule known as microRNA-483 enhanced the function of endothelial cells and eased the symptoms of pulmonary arterial hypertension (PAH) in rat models of the disease, a ... Read more

June 8, 2020June 8, 2020

Levosimendan Seen to Ease Pressure on Heart in High-need PH Patient Group

News

Six weeks of treatment with levosimendan significantly lowered pressure on the heart and improved physical capacity among people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), findings ... Read more